Won-Seog Kim

Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project

Wing-Yan Au, Dennis D. Weisenburger, Tanin Intragumtornchai et al. · Blood · 2008 · 741 citations

Medicine, Oncology, Otolaryngology +12

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study

Gustaaf W. van Imhoff, Andrew McMillan, Matthew J. Matasar et al. · Journal of Clinical Oncology · 2017 · 237 citations · Full text

Medicine, Immunology, Oncology +14

Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial

Matthew Ku, Mark P. Hertzberg, Huiqiang Huang et al. · The Lancet · 2024 · 142 citations

Medicine, Hematology, Oncology +15

Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project

Ranjana H. Advani, Tetiana Skrypets, Monica Civallero et al. · Blood · 2021 · 124 citations · Full text

Life Sciences, Hematology, Oncology +12

Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial

Michinori Ogura, Juan‐Manuel Sancho, Seok‐Goo Cho et al. · The Lancet Haematology · 2018 · 63 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +5